



# Landscape of costimulatory molecule signature in breast cancer and its prognostic significance

Changyuan Kang, Fen Yun, Lin Shi, Yongfeng Jia, Xia Liu

Department of Pathology, Basic Medicine College, Inner Mongolia Medical University, Hohhot, China

**Contributions:** (I) Conception and design: C Kang, Y Jia; (II) Administrative support: Y Jia, X Liu; (III) Provision of study materials or patients: F Yun, L Shi; (IV) Collection and assembly of data: C Kang, X Liu; (V) Data analysis and interpretation: C Kang, Y Jia; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Yong-Feng Jia; Xia Liu. Department of Pathology, Basic Medicine College, Inner Mongolia Medical University, Hohhot, China. Email: Yfjia0471@163.com; 18547139575@163.com.

**Background:** Breast cancer (BRCA) is the most common malignant tumor in the world. Because of its substantial heterogeneity, its clinical treatment is faced with various problems. Only a small number of patients can benefit from the treatment of immune checkpoint inhibitor (ICI). Costimulatory molecule signature (CMS) plays an essential role in T cell activation and antitumor immune response. Previous studies found that CMS is associated with prognosis-related immune response markers, suggesting that CMS may be a potential therapeutic target. However, the research on their function in BRCA subtype is still inadequate. Our study aims to analyze CMS in BRCA and establish an effective prognostic model.

**Methods:** We extracted 1,222 messenger RNA (mRNA) samples of 1,110 patients registered in the BRCA cohort of The Cancer Genome Atlas (TCGA), including 1,109 tumor tissue mRNA samples and 113 standard tissue samples for model construction and verification. The prognostic significance was determined by least absolute shrinkage and selection operator (LASSO)-Cox proportional hazard regression, which showed that the overall survival (OS) of the high-risk group was shorter than that of the low group ( $P < 0.01$ ).

**Results:** Although the CMS prognostic model can predict the prognosis well, the receiver operating characteristic (ROC) prediction results were unsatisfactory. The reason for this may be the heteromorphism of BRCA, so we divided the cases into four subtypes according to the PAM50 (PAM50Call\_RNAseq) in clinical information. The same method was used to construct the model in the four subtypes and verify the effect of each subtype prognostic model.

**Conclusions:** The results showed that the submodels constructed in this study can be used to evaluate the prognosis of each subtype.

**Keywords:** Breast cancer (BRCA); immunotherapy; immune checkpoint; B7-CD28; tumor necrosis factor (TNF)

Submitted Nov 08, 2022. Accepted for publication Jan 07, 2023. Published online Jan 13, 2023.

doi: 10.21037/atm-22-6245

**View this article at:** <https://dx.doi.org/10.21037/atm-22-6245>

## Introduction

Breast cancer (BRCA) has become the most common malignant tumor in women worldwide. Due to its heterogeneity, many mature drugs are not effective (1). New directions in therapy include administration of immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1 (PD-1) and PD-1 antibody and programmed

death-ligand 1 (PD-L1) antibody. They solve issues that cannot be avoided in the conventional treatment, such as a lack of apparent short-term effect, the inevitable side effects of chemotherapy on the treated patients, the inability to control disease progression over time, and poor outcome (2). ICI-based immunotherapy has developed well, and BRCA prognosis has improved (3,4). However, only a small portion of those with BRCA can obtain good outcomes from this

treatment (5). Therefore, means to determining the best candidates for immunotherapy and developing new immune detection targets are urgently needed.

ICI therapy cures tumors by restoring the interference of the tumor microenvironment (TME) on the activation and killing processes of immune cells such as T cells (6,7). Tumor cells are identified by T cell receptor (TCR) of natural killer T cell (NKT) to produce specific signals (8,9). Then, complete activation of T cells is completed by costimulatory molecule signature (CMS) (10). The expression of CMS in an inhibitory TME can change the normal activation process of immune cells (11,12). Therefore, ICI therapy can restore this immune abnormality to treat tumors (13).

CMS affects T cell activation, proliferation, survival, and cytokine secretion and plays an essential role in regulating tumor immunity (14). The B7 family consists of 8 molecules (*CD80*, *CD86*, *PD-L1*, *PD-L2*, *ICOSLG*, *B7-H3*, *B7x*, and *HHLA2*) (15), and the CD28 family consists of 5 molecules (*CD28*, *CTLA4*, *ICOS*, *PD-1*, and *TMIGD2*) (16). The 2 families come together to form the CD28-B7 family, from which PD-L1/PD-1 and CD86/CTLA4 belong to the immune checkpoint pathway (17,18). The tumor necrosis factor (TNF) ligand superfamily (TNFSF) and TNF receptor superfamily (TNFRSF) (19) compose the TNF family. There are 60 members in all, and some of them have been studied (20-22). However, these members' combined effect and clinical significance are unclear, so it is necessary to conduct a comprehensive study of these molecules in BRCA patients to find new treatment strategies.

With the great success of other solid tumors targeting ICIs in clinical applications, we seek to find a new CMS with specificity for guiding the clinical treatment of BRCA.

The CMSs with tumor-specific expression were selected. Then, through least absolute shrinkage and selection operator (LASSO) regression and cyclic Cox regression analysis of The Cancer Genome Atlas (TCGA) data set, the optimal variables for constructing the model were screened out, and the prognostic risk assessment model of CMS was constructed. However, TCGA within-group validation verification process did not yield good prediction results. We suspect this was due to the numerous molecular types within BRCA. The CMS prognostic model thus cannot accurately describe the overall BRCA prognosis results. Consequently, a CMS with different subtypes and normal tissues was developed. The same prediction model construction method was used to construct the new model, and within-group verification was performed, it has proved that the prognosis model established in various subtypes can effectively predict the prognosis.

For the first time, our work described the panoramic analysis of costimulatory molecules based on B7-CD28 and TNF family in all molecular subtypes of BRCA. A unique and effective prognosis model was established for each subtype, and the potential clinical application of costimulatory factors was emphasized, which provided theoretical support for the prognosis management and immunotherapy of various subtypes of BRCA patients. We present the following article in accordance with the TRIPOD reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-6245/rc>).

## Methods

### *Public messenger RNA (mRNA) expression datasets*

We systematically screened BRCA mRNA sequencing (mRNA-seq) data (TCGA-BRCA, 1,109 BRCA patients and 113 healthy controls' mRNA-seq data) from TCGA to explore the expression peculiarity, the prognosis information, and the response to treatment of CMS. An external test data set (GSE42568) was used for validation and downloaded from the Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>). All mRNA data processing standards were in line with public second-generation high-throughput sequencing platforms. Cases without clinical information or those with CMSs with low mRNA expression levels were removed (more than half of the samples had an expression value of 0). We screened the CMS expression of 1,089 BRCA patients to obtain the CMS panoramic and prognostic analysis (Table 1) (23).

### Highlight box

#### Key findings

- The landscape of CMS in BRCA was analyzed, and excellent prognosis models were established in each subtype.

#### What is known and what is new?

- CMS play an important role in the activation of T cells in tumor immune response, and mature drugs are available at present.
- Based on pathological cognition, an effective prognostic model of costimulatory factors of various subtypes of BRCA was established.

#### What is the implication, and what should change now?

- The model established in this study can effectively predict the prognosis of patients with different subtypes of BRCA, and put forward treatment suggestions.

**Table 1** Univariate Cox results of CMS in TCGA-BRCA

ID	Other names	Family	HR	HR.95L	HR.95H	P value
<i>CD274</i>	PD-L1, B7-H1	B7	0.90618937	0.7867342	1.04378223	0.1719938
<i>CD276</i>	B7-H3	B7	1.01515928	0.99844664	1.03215166	0.07566421
<i>CD80</i>	B7-1, CD28LG1	B7	1.03571376	0.72028877	1.48926796	0.84980565
<i>CD86</i>	B7-2, CD28LG2	B7	0.97834426	0.92597672	1.03367339	0.43537992
<i>HHLA2</i>	B7-H5	B7	0.00577569	3.14E-06	10.6219678	0.17899279
<i>ICOSLG</i>	B7-H2, CD275	B7	1.02407962	0.54605798	1.9205636	0.94088014
<i>PDCD1LG2</i>	PD-L2, B7DC, CD273	B7	0.91609046	0.8252223	1.01696443	0.10010595
<i>VTCN1</i>	B7-H4	B7	1.00004577	0.99887692	1.00121598	0.93886494
<i>CD28</i>	Tp44	CD28	0.9202512	0.79042151	1.07140591	0.28413443
<i>CTLA4</i>	CD152	CD28	0.90690926	0.8085523	1.01723093	0.09525997
<i>ICOS</i>	CD278, CVID1	CD28	0.90547788	0.79448975	1.03197076	0.13668113
<i>PDCD1</i>	PD-1, CD279	CD28	0.87735729	0.77405834	0.99444161	0.04064093
<i>TMIGD2</i>	CD28H	CD28	0.51849713	0.28556182	0.94143982	0.03090828
<i>CD27</i>	TNFRSF7	TNFRSF	0.95358065	0.91710989	0.99150176	0.0168985
<i>CD40</i>	TNFRSF5	TNFRSF	0.95739166	0.91889399	0.99750222	0.03758101
<i>EDA2R</i>	TNFRSF27, XEDAR	TNFRSF	1.29181983	1.13298695	1.47291941	0.00013064
<i>EDAR</i>	EDA-A1R	TNFRSF	0.83551011	0.48216856	1.44778651	0.52170969
<i>FAS</i>	TNFRSF6, CD95	TNFRSF	0.97408207	0.93029663	1.01992831	0.26311239
<i>LTBR</i>	TNFRSF3	TNFRSF	0.99635411	0.98044493	1.01252144	0.6564975
<i>NGFR</i>	TNFRSF16, CD271	TNFRSF	0.97383521	0.94130712	1.00748734	0.12611328
<i>RELT</i>	TNFRSF19L	TNFRSF	0.965696	0.80680521	1.15587846	0.70351811
<i>TNFRSF10A</i>	TRAILR1, CD261	TNFRSF	1.00741762	0.94370324	1.0754337	0.82454599
<i>TNFRSF10B</i>	TRAILR2, CD262	TNFRSF	0.98437014	0.9454612	1.02488032	0.44391584
<i>TNFRSF10C</i>	TRAILR3, CD263	TNFRSF	1.05310689	0.92669458	1.19676336	0.42772237
<i>TNFRSF10D</i>	TRAILR4, CD264	TNFRSF	0.99114626	0.90149916	1.08970807	0.85412494
<i>TNFRSF11A</i>	RANK, CD265	TNFRSF	0.98592928	0.86956738	1.11786225	0.82497562
<i>TNFRSF11B</i>	OPG	TNFRSF	0.99582722	0.96660156	1.02593653	0.78321104
<i>TNFRSF12A</i>	FN14, TWEAKR, CD266	TNFRSF	0.99615606	0.98849017	1.00388139	0.32850793
<i>TNFRSF13B</i>	TACI, TNFRSF14B, CD267	TNFRSF	0.62384324	0.37355545	1.04182763	0.07133195
<i>TNFRSF13C</i>	BAFFR, CD268	TNFRSF	0.87235258	0.74665819	1.01920669	0.08537683
<i>TNFRSF14</i>	LIGHTR, HVEM, CD270	TNFRSF	0.91186061	0.86843839	0.95745396	0.00021014
<i>TNFRSF17</i>	BCMA, TNFRSF13A, CD269	TNFRSF	0.94325224	0.87913362	1.01204727	0.10383219
<i>TNFRSF18</i>	GITR, AITR, CD357	TNFRSF	0.97597548	0.95314141	0.99935657	0.04408834
<i>TNFRSF19</i>	TROY, TAJ	TNFRSF	0.96305506	0.91754805	1.01081906	0.12744656
<i>TNFRSF1A</i>	TNFR1, CD120A	TNFRSF	0.99235135	0.97760473	1.00732041	0.31483092

Table 1 (Continued)

Table 1 (Continued)

ID	Other names	Family	HR	HR.95L	HR.95H	P value
<i>TNFRSF1B</i>	TNFR2, CD120B	TNFRSF	0.97809485	0.95894412	0.99762803	0.02813842
<i>TNFRSF21</i>	DR6, CD358	TNFRSF	1.00514255	0.99442978	1.01597073	0.34812118
<i>TNFRSF25</i>	DR3, TNFRSF12	TNFRSF	0.92387929	0.83601188	1.02098183	0.12048706
<i>TNFRSF4</i>	OX40, CD134	TNFRSF	0.97309554	0.89997603	1.05215571	0.49378071
<i>TNFRSF6B</i>	DCR3	TNFRSF	NA	NA	NA	NA
<i>TNFRSF8</i>	CD30	TNFRSF	0.48173788	0.28956709	0.80144252	0.0049197
<i>TNFRSF9</i>	4-1BB, CD137, ILA	TNFRSF	0.78840241	0.61154183	1.01641184	0.06659995
<i>CD40LG</i>	TNFSF5, CD154, CD40L	TNFSF	0.82331268	0.69350165	0.977422	0.02636278
<i>CD70</i>	TNFSF7, CD27L	TNFSF	0.84588855	0.65764939	1.08800747	0.19250822
<i>EDA</i>	EDA-A1, EDA-A2	TNFSF	1.31909047	0.95053491	1.83054787	0.09761617
<i>FASLG</i>	TNFSF6, CD95-L	TNFSF	0.80943956	0.65790002	0.99588445	0.04561293
<i>LTA</i>	TNFSF1	TNFSF	0.82120529	0.66552639	1.01330036	0.06624502
<i>LTB</i>	TNFSF3	TNFSF	0.98654754	0.97088894	1.00245868	0.09708761
<i>TNF</i>	TNFSF2, TNFA	TNFSF	0.97181714	0.90327616	1.04555904	0.44362768
<i>TNFSF10</i>	TRAIL, CD253	TNFSF	1.00088224	0.99833159	1.0034394	0.4981763
<i>TNFSF11</i>	RANKL, CD254	TNFSF	1.00011272	0.96997313	1.03118882	0.99423978
<i>TNFSF12</i>	TWEAK	TNFSF	0.96807948	0.93932971	0.99770919	0.03493894
<i>TNFSF13</i>	APRIL, CD256	TNFSF	0.99666685	0.95142363	1.04406152	0.88798362
<i>TNFSF13B</i>	BAFF, CD257	TNFSF	0.96769873	0.92700724	1.01017641	0.13412644
<i>TNFSF14</i>	LIGHT, HVEM, CD258	TNFSF	0.71933172	0.49533846	1.04461528	0.0835128
<i>TNFSF15</i>	TL1A	TNFSF	0.94484839	0.84370713	1.05811417	0.32605969
<i>TNFSF18</i>	GITRL	TNFSF	1.05339076	0.70728115	1.56886988	0.79800763
<i>TNFSF4</i>	OX-40L, CD134L, CD252	TNFSF	1.12176372	1.02793224	1.22416029	0.00993467
<i>TNFSF8</i>	CD30L, CD153	TNFSF	0.91126814	0.76686072	1.08286891	0.291174
<i>TNFSF9</i>	4-1BB-L, CD137L	TNFSF	1.03716052	0.94076189	1.14343699	0.46351416

CMS, costimulatory molecule signature; TCGA, The Cancer Genome Atlas; BRCA, breast cancer; HR, hazard ratio; HR.95L, HR with low 95% CI; CI, confidence index; HR.95H, HR with high 95% CI; TNFRSF, TNF receptor superfamily; TNF, tumor necrosis factor; TNFSF, TNF ligand superfamily; NA, not available.

We further selected 4 recognized molecular subtypes of BRCA (<https://xena.ucsc.edu/>): basal-like BRCA (BASAL), human epidermal growth factor receptor 2-enriched BRCA (HER2), luminal A BRCA (LUMA), and luminal B BRCA (LUMB) (24). The tumor-specific CMSs of each subtype were screened ( $P < 0.05$ ) and combined with the corresponding survival time information. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

### Validation

According to the above-mentioned tumor subtypes, we screened the mRNA data of tumor-specific CMSs corresponding to each subtype. Then, through LASSO regression and cyclic Cox regression analysis of TCGA-BRCA data set, the optimal variables for constructing the model were screened out, and the prognostic risk assessment model of CMS (BRCA-model) was constructed.

The survival rate of each patient was calculated in the form of nomogram. TCGA-BRCA cases were randomly divided into a training group and test group. According to the “Surv-Cutpoint” function in the “Survminer” R software package (The R Foundation for Statistical Computing, USA), the optimal cutpoint was determined. The external validation data set was selected from the GEO database (GSE42568). Patients from all the cohorts were divided into high-risk and low-risk groups. The Kaplan-Meier curve and the double-tailed logarithmic rank-sum test were used to calculate the prognostic model (25). The CMS expression heat map of the model, receiver operating characteristic (ROC) area prediction survival curve (26), and multiple-factor Cox analysis with other clinical traits proved that the model could be used as an independent prognostic predictor. Therefore, our work describes the overall prospect of CMS based on the CD28-B7 and TNF family and highlights the potential clinical application of CMS: supporting the theoretical development of prognosis management and immunotherapy for BRCA subtypes.

### **Functional enrichment analysis**

After building a predictive model, the sample cases were scored and divided into high-risk and low-risk groups for comparison and obtained the difference genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to analyze the target genes' biochemical reaction, molecular function, and cell component enrichment. It was found that these genes were enriched in biological functions such as monooxygenase, endopeptidase, oxidoreductase activity, and multicellular homeostasis.

### **Estimation of the characteristics of immune cell infiltration**

We used CIBERSORT and the fragments per kilobase million (FPKM) of TCGA-BRCA RNA sequencing (RNA-seq) data to estimate the scores of 22 immune cell types in BRCA's TME. The leukocyte gene marker matrix *LM22* of CIBERSORT software was used to complete the analysis of various immune cell types. *LM22* comprises 547 genes, with 22 kinds of immune cells, including different subtypes of B cell type, T cell type, NK cells, plasma cells, and myeloid cells (27).

### **Biomarkers predicting immune response**

The predictive performance of the potential immunotherapy response of CMS was evaluated with the following biomarkers: immune checkpoints, immunosuppressive factors, chemokines, and major histocompatibility complex (MHC) molecules. The bubble diagram suggested that CMS strongly correlated with molecules in each stage of the immune process (28).


### **Statistical analysis**

The outcome of the BRCA-model was not ideal when the ROC curve was used to predict the model effect. This was likely due to the considerable heterogeneity of BRCA. We therefore divided TCGA-BRCA data into BASAL, HER2, LUMA, and LUMB types. The expression of CMS in each subtype was comprehensively analyzed. The prognosis analysis was carried out based on CMS, and the same method was used to construct the CMS prognostic model based on each subtype. Valuable results were obtained from the verification of the ROC curve in the random block.  $P < 0.05$  was considered statistically significant for all statistical methods.


## **Results**

### **CMS panoramic analysis**

We examined overall picture and prognostic significance of CMS genes in BRCA. The genes identified in this study included 13 CD28-B7 family members and 47 TNF family members. The co-expression of these molecules is shown in *Figure 1*. We found that there is a high correlation between CMS. Then, the matched clinical system information was combined with the expression data of 60 CMSs from 1,097 BRCA patients to calculate the prognosis information of CMS (*Table 1*). We then screened the CMSs that were specifically expressed in tumor tissues (tumor-specific CMSs). In tumor-specific CMSs, there were 10 genes with high-risk factors [hazard ratio (HR)  $> 1$ ] and 32 genes with low risk-factors (HR  $< 1$ ). In addition, we divided BRCA into 4 subtypes, BASAL, HER2, LUMA, and LUMB, according to molecular typing (PAM50) and then compared 60 CMSs with the expression levels of normal tissues (*Figure 2*). In the subsequent establishment of the prognostic model, CMSs



**Figure 1** Correlation between CMSs in TCGA-BRCA. CMS, costimulatory molecule signature; TCGA, The Cancer Genome Atlas; BRCA, breast cancer.



**Figure 2** Comparison of mRNA expression levels among different molecular subtypes and with standard samples in TCGA-BRCA. \*P<0.05; \*\*\*\*P<0.0001; ns, P>0.05 (adjusted P values). BASAL, basal-like BRCA; HER2, human epidermal growth factor receptor 2-enriched BRCA; LUMA, luminal A BRCA; LUMB, luminal B BRCA; mRNA, messenger RNA; TCGA, The Cancer Genome Atlas; BRCA, breast cancer.

with different subtypes and normal tissues were screened for candidate genes.

### Identification of CMS for prediction

Based on the clinical information of 1,086 patients and the mRNA data of 42 tumor-specific genes, the optimal adjustment parameter  $\lambda$  was determined by the LASSO regression algorithm and cross-validation method, and the optimal variables were determined (*TNFRSF14*, *TNFRSF19*, *TNFSF9*, *EDA*, *EDA2R*, *TNFSF14*) to construct the prediction model (Figure 3A). Then, we used these parameter genes to develop a risk model based on the gene expression level for BRCA patients after several cycles of stepwise Cox regression analysis to predict the survival rate of patients using the following formula: model assessment risk score = (expression level of *TNFRSF14*  $\times$   $-0.117170916$  + expression level of *TNFRSF19*  $\times$   $-0.135304566$  + expression level of *TNFSF9*  $\times$   $0.255634182$  + expression level of *EDA2R*  $\times$   $0.372627814$ ) (Figure 3B, Table 2). For clinical application, we detected the expression level data of these 4 indicators of patients with BRCA with the second-generation high-throughput sequencing technique. Patients' risks can be calculated by the above model and patients can be divided into high-risk patients and low-risk patients according to the optimal cutpoint. The results of univariate and multivariate Cox analyses of the model score, age, gender, and clinical stage showed that the risk score of model assessment could not independently evaluate the prognostic risk level (Figure 3C, 3D). The survival prediction model is given in the form of a nomogram (Figure 3E).

Next, we randomly divided the BRCA samples into a training group and a test group, and a high-risk group and a low-risk group according to the best cutoff point of the prediction model score. Patients in the high-risk group showed significantly worse prognoses (Figure 4A) (18). Further, we use ROC curve to verify and evaluate the prediction effect of the model (Figure 4B); area under the curve (AUC) training = 0.665; AUC test = 0.711; AUC > 0.5 indicates that the prediction results of the model are reliable (19). In order to determine whether the model gene expression trend was the same as that for a random block, the model gene expression of the model was extracted to draw a heat map (Figure 4C). Patients in each group were ranked according to the risk score from low to high, with a higher risk score indicating a higher probability of death

(Figure 4D).

### External dataset validation


GSE42568 was performed by GPL570 (Affymetrix Human Genome U133 Plus 2.0 array) including 104 BRCA tumor samples and 17 nontumor samples as normal controls. The consistent statistical method mentioned above was used for validation (Figure 5). Although the prognostic model we developed proved to be effective after verification, the actual effect was not as good as expected. Because of the pathological background, the results were attributed to the tumor heterogeneity of BRCA, so BRCA was grouped according to molecular typing (PAM50).

### Construction and validation of the CMS in the 4 subtypes

According to the clinical data of TCGA-BRCA collected by UCSC Xena (<https://xena.ucsc.edu/>), 1,089 patients were divided into BASAL (n=139), HER2 (n=69), LUMA (n=415), and LUMB (n=185) subtypes. The CMS prognosis model of each subtype was established and verified using the same statistical method. Each subtype has a good predictive effect, which confirms the speculation that the heterogeneity of BRCA leads to a poor prognosis model. The results are shown in Figure 6. There were significant differences in the low-risk groups of the high-risk groups in each subtype, and they could be used as independent prognostic factors to evaluate the prognosis.

### Biological processes and pathways related to CMS

The CMS prognostic models of each subtype [BASAL (n=139), HER2 (n=69), LUMA (n=415), and LUMB (n=185)] confirmed that CMS could clearly and effectively predict the prognosis, so we studied the biological mechanism further. According to the median of the model assessment risk score, the patients were divided into high-risk patients and low-risk patients. The differential analysis of the two groups of patients screened 75 differentially expressed genes and then selected these selected genes for GO and KEGG analysis. The results showed that the characteristic genes were concentrated in the redox reaction and the oxidoreductase activity acting on complement binding (Figure 7A). These results were further confirmed by KEGG analysis (Figure 7B).




**Figure 3** Prognostic model construction process. (A) LASSO regression algorithm and a cross-validation method were used to determine the optimal adjustment parameters according to the minimum variance. (B) Prediction model results and the corresponding coefficient of model variable genes. (C) Univariate Cox analysis of the model assessment risk score and other related clinical information. (D) Multivariate Cox analysis of the model assessment risk score and other related clinical information. (E) The formula for calculating the 1-, 5-, and 10-year survival rate of patients are represented by nomogram. CI, confidence interval; LASSO, least absolute shrinkage and selection operator.




**Table 2** Results of the CMS prognostic model based on TCGA-BRCA

ID	Coef	HR	HR.95L	HR.95H	P value
TNFRSF14	-0.1171709	0.88943316	0.83176602	0.95109843	0.00061271
TNFRSF19	-0.1353046	0.87344985	0.80216791	0.95106601	0.00183919
TNFSF9	0.25563418	1.29128027	1.07394771	1.55259396	0.00655425
EDA2R	0.37262781	1.45154399	1.24302303	1.695045	2.48E-06

CMS, costimulatory molecule signature; TCGA, The Cancer Genome Atlas; BRCA, breast cancer; coef, coefficient; HR, hazard ratio; HR.95L, HR with low 95% CI; CI, confidence index; HR.95H, HR with high 95% CI; TNFRSF, TNF receptor superfamily; TNF, tumor necrosis factor; TNFSF, TNF ligand superfamily.



**Figure 4** Validation of model effect. (A) The BRCA cohort was randomly divided into BRCA-TRAIN and BRCA-TEST groups. (B) The survival curve of ROC area prediction (BRCA-TRAIN, and BRCA-TEST). (C) Heat map of the model gene expression (BRCA-TRAIN, and BRCA-TEST). (D) The risk scores of the BRCA-TRAIN, and BRCA-TEST groups were evaluated according to the above model, and the cases corresponded to the survival status. The blue dot in the picture represents the patient who is not dead, and the red dot represents the patient who is already dead. With the increase in the risk scores evaluated by the model, the deadly events in the cases increased. BRCA, breast cancer; ROC, receiver operating characteristic; AUC, area under the curve.




**Figure 5** External dataset validation. The verification of the external geographic data set is performed by using the statistical method consistent with that of *Figure 4*. The blue dot in the picture represents the patient who is not dead, and the red dot represents the patient who is already dead. GEO, Gene Expression Omnibus; ROC, receiver operating characteristic; AUC, area under the curve.


### *CMS-related immune cell infiltration and inflammatory activity*

We used the combination of CIBERSORT and *LM22* to calculate the estimated scores of different immune cells in the TME of BRCA (*Figure 8A*). According to the

prognostic model score, the patients were divided into high-risk and low-risk patients. The results showed that B memory cells, activated dendritic cells (DCs) and M0 macrophages were highly infiltrated in high-risk patients, but this was not obvious. The ratio of CD8<sup>+</sup> T cells and activated mast cells in low-risk patients is higher than that



**Figure 6** Establishment of a prognostic model for the (A) BASAL, (B) HER2, (C) LUMA, and (D) LUMB subtype CMS. Validation was performed according to the same method as described above. CI, confidence index; BASAL, basal-like breast cancer; HER2, human epidermal growth factor receptor 2-enriched breast cancer; LUMA, luminal A breast cancer; LUMB, luminal B breast cancer; CMS, costimulatory molecule signature.



**Figure 7** Functional enrichment analysis. (A) GO enrichment analysis. (B) KEGG enrichment analysis. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

in high-risk patients (*Figure 8B*).

**CMS and biomarkers for predicting immunotherapy response**

The predictive performance of the immunotherapy response of CMS was evaluated by the following biomarkers: MHC molecules, immune-stimulating factors, immune checkpoints, immunosuppressive factors, and chemokines. The bubble diagram (*Figure 9*) suggested that CMS strongly correlated with the molecules in each stage of the immune process; that is, the model gene may in fact play a greater role in clinical application than indicated by the data.


**Immunotherapy response analysis of characteristic costimulatory factor EDA2R**

Macroscopically, we found that the high-risk costimulatory factor *EDA2R* had adverse prognostic significance and appeared in many prediction models. BRCA-TCGA data were used for single-gene analysis, and we speculated that *EDA2R* had crucial biological significance based on the data

results. The two groups of samples were evaluated with the Wilcoxon test. We used a forest map (*Figure 10*), with R version 4.2.1 software for statistical analysis, to show each variable [including HR, 95% confidence interval (CI), and P value]. Each subtype showed statistical significance (if not otherwise stated, the rank-sum test detected two sets of data, with a P value <0.05 being considered statistically significant). Nonetheless, the HR values were not the same, and it is indicated that the mechanism may be different in different cancers (29).

The expression and distribution of *EDA2R* in different subtypes of tumor tissues and normal tissues (*Figure 11*). The transverse axis represents different tumor tissues, the longitudinal axis represents the expression and distribution of the *EDA2R* gene, and different colors represent different groups. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, asterisks (\*) stand for significance levels (30).

Verification of the immune correlation of *EDA2R* in various subtypes. Spearman correlation analysis hot map of *EDA2R* immune correlation and *EDA2R* gene expression in multiple tumor tissues (*Figure 12A*). The transverse axis represents different tumor tissues, the longitudinal



**Figure 8** Estimation of the characteristics of immune cell infiltration. (A) The CIBERSORT R package predicted the immune cell infiltration of BRCA. (B) The CMS model score in this study divided BRCA patients into two groups, high and low risk, to observe differences in immune cells. BRCA, breast cancer; CMS, costimulatory molecule signature.


axis represents different immune scores, and the different colors represent the correlation coefficient. The negative value represents negative correlation, and the positive value represents positive correlation; the stronger the correlation is, the deeper the color (31).

Mutation analysis of *EDA2R* and each subtype. Relationship with tumor mutation load: Spearman correlation analysis of tumoral mutational burden (TMB) and *EDA2R* gene expression (Figure 12B). The horizontal axis represents the correlation coefficient between the gene and TMB, and the ordinate is the different tumors. The dot size represents the correlation coefficient, and the different colors represent the P value; the bluer the color is, the smaller is the P value (32).


Relationship between *EDA2R* and microsatellite instability (MSI). Spearman correlation analysis of MSI and *EDA2R* gene expression (Figure 12C). The horizontal axis

represents the correlation coefficient between the gene and TMB, and the ordinate is the different tumors. The dot size represents the correlation coefficient, and the different colors represent the P value the darker the color is, the smaller is the P value (33).

The gene expression data of *EDA2R* in TCGA-BRCA were selected, and BRCA patients were divided into high group and low groups according to the median expression data. Differentiated genes were obtained by difference analysis between the high and low groups. The functional enrichment analysis of these differential genes was performed (Figure 12D). Combined with the correlation of immune cells, we found that *EDA2R* was related to type 1 helper (Th1) CD4<sup>+</sup> T cells and NKT cells in different degrees. We believe that *EDA2R* plays an important role in the immune signal mediation of these immune cells in BRCA immune microenvironment.



**Figure 9** Correlation between the BRCA CMS model genes and the treatment-related biomarkers. BRCA, breast cancer; CMS, costimulatory molecule signature.



**Figure 10** Univariate Cox results for each subtype. CI, confidence index; BASAL, basal-like breast cancer; HER2, human epidermal growth factor receptor 2-enriched breast cancer; LUMA, luminal A breast cancer; LUMB, luminal B breast cancer; BRCA, breast cancer.


**Drug sensitivity analysis of the CMS prognostic model**

We predicted the chemotherapeutic response for each sample based on the largest publicly available pharmacogenomics

database [the Genomics of Drug Sensitivity in Cancer (GDSC); <https://www.cancerrxgene.org>]. The prediction process was implemented by the R package “pRRophetic”. The samples’ half-maximal inhibitory concentration (IC<sub>50</sub>) was estimated by ridge regression. All parameters were set as the default values. Using the batch effect of combat and tissue type of all tissues, we summarized the duplicate gene expression as the mean value. As calculated by this model, we found that some drugs may be therapeutically effective in high-risk patients (IC<sub>50</sub> high risk < IC<sub>50</sub> low risk) (Figure 13).

**Benefits of ICI’s treatment**

We use the *PD-L1* expression level to assess the potential impact of ICI’s therapy on BRCA patients under our risk model. The results showed that the *PD-L1* expression level of high-risk subgroup was lower than that of low-risk subgroup. This means that patients in low-risk group benefit more from ICI’s treatment than patients in high-risk group (Figure 14).



**Figure 11** Expression of *EDA2R* in each subtype. \*\*\* $P < 0.001$ . TPM, transcripts per million; TCGA, The Cancer Genome Atlas; BASAL, basal-like breast cancer; HER2, human epidermal growth factor receptor 2-enriched breast cancer; LUMA, luminal A breast cancer; LUMB, luminal B breast cancer.

## Discussion


A large body of evidence shows that physical and biochemical depletion of T cells is the main feature of an inhibitory TME (34). CMS plays an essential role in the killing of tumor by immune cells. In addition, PD-L1/PD-1 drugs have received good results in solid tumors, such as bladder cancer and lung cancer (35,36). CMS is mainly composed of the CD28-B7 and TNF families. In this study, the expression patterns of 60 CMSs in BRCA patients were detected. Based on the expression of CMS, we screened the expression data of tumor-specific CMSs in TCGA data and developed a new survival prediction model. However, the results were unsatisfactory in the TCGA-BRCA samples random validation. From the perspective of clinicopathology, this can be attributed to the substantial heterogeneity of BRCA. Subsequently, according to the clinical information provided by the UCSC, we divide the cases into 4 subtypes: BASAL, LUMA, LUMB, and HER2. According to the same statistical method and packages from R, the 4 subtypes were used to establish a predictive model with tumor-specific CMSs. We verified the model within the random group. The CMS prediction model risk score was an independent risk factor for BRCA subtypes. We also explored the immune landscape (including immune cell distribution and inflammatory activity) of CMS high-risk and low-risk patients. We found that CMS scores were positively correlated with different immunotherapy biomarkers. Our study is the first and most comprehensive study to date to describe the predictive value of CMS for prognosis and immunotherapy response in BRCA patients.

The results of the CMS model of each subtype of BRCA showed that *TNFRSF14*<sup>+</sup>, *TNFRSF4*<sup>+</sup>, *TNFRSF19*<sup>+</sup>, *TNFRSF10A*<sup>+</sup>, *LTA*<sup>+</sup>, *TNFSF9*<sup>+</sup>, *TNFRSF8*<sup>+</sup>, *TNFSF4*<sup>+</sup>,

*EDA*<sup>+</sup>, *TNFSF14*<sup>+</sup> T, *NFRSF1B*<sup>+</sup>, *LTBR*<sup>+</sup>, *TNFSF13B*<sup>+</sup>, *TNFRSF17*<sup>+</sup>, *CD27*<sup>+</sup>, *EDA2R*, and *CD40LG* all belonged to the TNF family. This indicates that costimulatory signals and pathways in the TNF family have greater prognostic value in BRCA patients than do those of the CD28-B7 family. Among them, *EDA2R*<sup>+</sup>, *CD40LG*<sup>+</sup>, *PDCD1*<sup>+</sup>, and *TNFRSF14*<sup>+</sup> showed prognostic significance in the panoramic analysis of CMS and repeatedly appeared in the prediction models of each subtype. Their biological functional significance also warrants further attention.

*EDA2R*, also known as *TNFRSF27*, or *XEDAR*, has been studied previously, but its function and signal mechanism are still unclear. *XEDAR* can activate typical nuclear factor- $\kappa$ B (NF- $\kappa$ B) pathways and atypical NF- $\kappa$ B signaling pathways by direct interaction with TRAF3 and TRAF6 (37). Some researchers have found that *EDA2R* can reduce the inflammatory effect of cell injury through the NF- $\kappa$ B pathway (38). The atypical NF- $\kappa$ B signal induced by *XEDAR* involves NF- $\kappa$ B inducing kinase (NIK) and inhibitor of kappa B kinase  $\alpha$  (IKK $\alpha$ ) and is negatively regulated by TRAF3, cIAP, and A20 (39). It had also been reported that in most BRCA, *XEDAR* expression is downregulated via promoter methylation blocking the *XEDAR*-mediated cell death pathway. Restoring *XEDAR* expression by demethylation therapy may be a novel approach for BRCA treatment (40). *EDA2R*, as a high-risk immunostimulatory factor, appeared in the single-factor Cox, BRCA, and LUMA prediction model. Its actual prognostic and therapeutic value in BRCA, has not been entirely clarified. This study provides data for directing the further study of *EDA2R* in LUMA.

*CD40LG*, also known as *CD40L*, *TNFSF5*, or *CD154*, is a membrane-bound protein belonging to the TNFSF




**Figure 12** Immunotherapy response analysis of *EDA2R*. (A) Relationship between the *EDA2R* subtypes and immune-related parameters. (B) Correlation between *EDA2R* and TMB for each subtype. (C) Correlation between *EDA2R* and MSI in the various subtypes. (D) According to the expression level of *EDA2R* in TCGA-BRCA, the patients were divided into two groups. Functional enrichment analysis was carried out on the differential genes obtained from the comparison between groups. HER2, human epidermal growth factor receptor 2-enriched breast cancer; BASAL, basal-like breast cancer; LUMA, luminal A breast cancer; LUMB, luminal B breast cancer; TMB, tumoral mutational burden; MSI, microsatellite instability; TCGA, The Cancer Genome Atlas; BRCA, breast cancer.

family. It is mainly expressed after activating CD4<sup>+</sup> T cells and binds to CD40 molecules on the surface of mature B cells. It assists in the maturation and activation of B cells

and plays a vital role in immune response. A study suggests that the characteristics of CD40LG triggering Th1 immune response can be used as a new therapeutic target (41). It was






**Figure 13** Sensitive drugs in high-risk patients (JNK inhibitor VII, PF.4708671 v, CMK, BMS.708163, BIBW2992, AICAR, ABT.263). IC<sub>50</sub>, half-maximal inhibitory concentration.

found that P2Y12-dependent CD40L, which is dependent on platelet-releasing cells, can further activate the CD40 receptors on the surface of CD8<sup>+</sup> T cells and inhibit tumor growth, thus providing a new therapeutic direction for platelets control liver tumor (42). It has been reported that the expression of the CD40LG-CD40 axis in lung cancer can significantly improve prognosis of lung cancer patients (43). Some cytokines can be secreted to enhance the immune response after binding with CD40 expressed by B cells and tumor cells. For example, after CD40LG combines with Hodgkin lymphoma cells, protumor inflammatory factors such as interleukin-8 (IL-8) and IL-6 are produced. DCs

can produce more IL-12 than can CD40L or interferon- $\gamma$  (IFN- $\gamma$ ) alone under the combined action of CD40L and IFN- $\gamma$  (44). CD40LG, after binding, interacts with surviving c-MYC, hTERT, and other apoptosis-related genes to induce apoptosis (45). An in-depth study of the biochemical mechanism of CD40 ligand-induced tumor cell apoptosis may provide a new direction for clinical tumor treatment.

The inhibitory receptor on T cells activated by the PDCD1 antigen is the mechanism for organisms to avoid excessive immunity in evolution, which plays a crucial role in inducing and maintaining immune tolerance (46).



**Figure 14** The effect of immunotherapy was reflected by the expression of CD274 (PD-L1) in high-risk and low-risk groups. The results indicated that low-risk patients may get better results under immunotherapy. PD-L1, programmed death-ligand 1.

Inhibitory signals are released when combined with CD274/PDCD1L1 and CD273/PDCD1LG2 (47). After TCR is involved, PDCD1 is associated with CD3-TCR in immune synapses and directly inhibits T cell activation (through similarity) (48). After ligand binding, PDCD1 is phosphorylated, and then PTPN11/SHP-2 is recruited to mediate the dephosphorylation of ZAP70, PRKCQ/PKCtheta, and CD247/CD3zeta, resulting in inhibition of T-cell activation (49). Long-term stimulation of tumor antigen leads to the continuous secretion of inflammatory factors, which can continuously increase the expression of PD-1 in T cells, leading to long-term activation of T cells and functional depletion (50). PDCD1 is highly expressed in the BASAL type, which is an important reason why BASAL has a more potent immune escape effect than do other subtypes of BRCA. As the treatment for PDCD1 locus in the BASAL subtype is unknown, we will further investigate it in future studies.

*TNFRSF14* (also known as *LIGHTER*), *TNFSF14* (*LIGHT*), *LTA*/lymphotoxin- $\alpha$ , immunoglobulin member *BTLA*, and *CD160* constitute a complex stimulation inhibition signal network (51). *TNFRSF14* acts as a ligand for *BTLA* in mucosa-associated lymphoid tissue, and its inactivation can release the activity of T cells and promote its killing of malignant B cells (52). *TNFRSF14* can also promote the survival and differentiation of immune

cells through the TRAF2-TRAF3 E3 ligase signaling pathway (53). The *LIGHT* expressed in DCs stimulates the activation and proliferation of T cells. In contrast, *LIGHTER* stimulates the NF- $\kappa$ B pathway in T cells and preferentially induces the expression of (54). Interaction with *CD160* on NK cells enhances IFN- $\gamma$  production and antitumor immune response (55). *TNFRSF14* may induce apoptosis and inhibit the proliferation of bladder cancer cells *in vitro* (56). The mutation rate of *TNFRSF14* in follicular lymphoma is as high as 39%. It is speculated that the lack of tumor suppressor function of *TNFRSF14* leads to the formation of follicular lymphoma (57). In our study, *TNFRSF14* was found to be a low-risk factor (HR = 0.889 < 1). We speculate that *TNFRSF14* also plays a tumor-suppressing role in BRCA, which may be useful for future BRCA treatment.

This study highlights that CMSs may predict the response of BRCA patients to therapy. Since immune checkpoint targets (PD-L1/PD-1, *CD86/CTLA4*) are CMSs, CMSs may have the ability to predict ICI immunotherapy response. Due to the lack of details about mRNA expression in the immune microenvironment, we must evaluate this relationship indirectly. We collected the TMB, MSI, and immune correlation. TMB is one of the classic biomarkers of immunotherapy response, and TMB always increases the load of new antigens. MSI is a predictive immunotherapy biomarker that is considered more accurate than TMB or PD-L1 expression. From the data of TMB and MSI, we found that the low-risk patients under our model may have a better response to immunotherapy, which is the same as the result of immunocytogram analysis.

In the later research, PD-L1, the best index of immunotherapy, was predicted to evaluate the guiding significance of this risk model for immunotherapy. We calculated the risk score of patients with TCGA-BRCA by the risk model in our study and divided them into high-risk group and low-risk group by median. At the same time, PD-L1 was extracted from the patient mRNA data. Through the comparison between the high-risk group and the low-risk group, we found that the expression level of PD-L1 in the low-risk group was higher, which shows that the low-risk patients calculated by this model will have a better effect on immunotherapy. This result is consistent with previous infiltration of immune cell: There is a higher degree of CD8<sup>+</sup> T cell infiltration in low-risk patients. This result also means that low-risk patients have a more obvious effect on immunotherapy. In addition, in the previous discussion, we analyzed the key factor *EDA2R*,

and found that *EDA2R* was negatively correlated with the Th1 CD4<sup>+</sup> T cells, and Th1 CD4<sup>+</sup> T cells mainly promoted tumor immunity, which further confirmed that the low-risk patients calculated by our risk model would gain more benefits from immunotherapy than those with high risk.

Generally speaking, we believe that the higher the TMB and MSI of a case are, the higher is the immunogenicity of the solid tumor in this case. The key genes in this model were negatively correlated with these indices in various subtypes, so we speculate that the low-risk patients calculated by this model algorithm have better response and receive greater effects from immunotherapy. In addition, we performed a drug sensitivity analysis for this prognostic model and found that 7 drugs (JNK inhibitor VIII, PF.4708671, CMK, BMS.708163, BIBW2992, AICAR, ABT.263) were sensitive and effective in high-risk patients. Comparing the model CMS with these different validated biomarkers, we can roughly speculate that different risk patients might be suitable for immunotherapy or combination therapy. These findings provide us with additional confidence in asserting that both the CMS score and the biological characteristics of the CMS itself may serve as novel predictive biomarkers for immunotherapy responses.

This study has some limitations. First, we only verified the reliability of the prognostic models at the data level. Secondly, the CMS-specific immune landscape was clarified by bioinformatics methods of RNA-seq data and thus might have been affected by data deletion errors. Thirdly, the mRNA expression data of patients after immunotherapy could not be obtained. CMS's ability to predict immunotherapy effects could only be reflected indirectly. With the accumulation and enrichment of future research data, CMS' significance and clinical application in the breast will increase.

## Conclusions

In a word, we comprehensively analyzed the expression of costimulatory factors in BRCA patients, and established costimulatory factor-related models for different subtypes of BRCA to predict the prognosis of BRCA patients. We also generated a nomogram to predict the survival rate of patients. We analyzed the characteristics of immune cell infiltration, immunotherapy response index and chemosensitivity of BRCA patients with different risk levels. Finally, we summarize the results, and screen out the potential treatment methods for patients with different risk

levels under the model.

## Acknowledgments

The results of this study are based on the data from TCGA (<https://www.cancer.gov/tcga>) and UCSC Genome Database. We thank all the authors who provided the data for these databases.

*Funding:* This article was supported by the Science and Technology Major Project of Inner Mongolia, China (No. 2019GG083).

## Footnote

*Reporting Checklist:* The authors have completed the TRIPOD reporting checklist. Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-6245/rc>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-6245/coif>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer* 2007;109:1721-8.

2. Keenan TE, Tolaney SM. Role of Immunotherapy in Triple-Negative Breast Cancer. *J Natl Compr Canc Netw* 2020;18:479-89.
3. El Bairi K, Haynes HR, Blackley E, et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. *NPJ Breast Cancer* 2021;7:150.
4. Henriques B, Mendes F, Martins D. Immunotherapy in Breast Cancer: When, How, and What Challenges? *Biomedicines* 2021;9:1687.
5. Kwa MJ, Adams S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. *Cancer* 2018;124:2086-103.
6. Nurieva R, Thomas S, Nguyen T, et al. T-cell tolerance or function is determined by combinatorial costimulatory signals. *EMBO J* 2006;25:2623-33.
7. Singh S, Hassan D, Aldawsari HM, et al. Immune checkpoint inhibitors: a promising anticancer therapy. *Drug Discov Today* 2020;25:223-9.
8. Davari K, Holland T, Prassmayer L, et al. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy. *J Immunother Cancer* 2021;9:e002035.
9. Sun L, Kees T, Almeida AS, et al. Activating a collaborative innate-adaptive immune response to control metastasis. *Cancer Cell* 2021;39:1361-74.e9.
10. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. *Immunity* 1995;2:555-9.
11. Goronzy JJ, Weyand CM. T-cell co-stimulatory pathways in autoimmunity. *Arthritis Res Ther* 2008;10 Suppl 1:S3.
12. Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. *Cell* 2019;176:677.
13. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. *Immunol Rev* 2008;224:166-82.
14. Ward-Kavanagh LK, Lin WW, Šedý JR, et al. The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. *Immunity* 2016;44:1005-19.
15. Mohammadi A, Najafi S, Amini M, et al. The potential of B7-H6 as a therapeutic target in cancer immunotherapy. *Life Sci* 2022;304:120709.
16. Ren X, Li Y, Nishimura C, et al. Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. *Genes Dis* 2022;9:1181-93.
17. Janakiram M, Chinai JM, Zhao A, et al. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. *Oncoimmunology* 2015;4:e1026534.
18. Zhang C, Zhang Z, Li F, et al. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma. *Oncoimmunology* 2018;7:e1461304.
19. Dostert C, Grusdat M, Letellier E, et al. The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond. *Physiol Rev* 2019;99:115-60.
20. Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. *Nat Rev Drug Discov* 2013;12:147-68.
21. Schildberg FA, Klein SR, Freeman GJ, et al. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. *Immunity* 2016;44:955-72.
22. Benhamouda N, Sam I, Epailard N, et al. Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma. *Clin Cancer Res* 2022;28:4983-94.
23. Chen Z, Yang F, Liu H, et al. Identification of a nomogram based on an 8-lncRNA signature as a novel diagnostic biomarker for childhood acute lymphoblastic leukemia. *Aging (Albany NY)* 2021;13:15548-68.
24. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin Oncol* 2009;27:1160-7.
25. Zhang Z, Lin E, Zhuang H, et al. Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma. *Cancer Cell Int* 2020;20:27.
26. Brentnall AR, Cuzick J. Use of the concordance index for predictors of censored survival data. *Stat Methods Med Res* 2018;27:2359-73.
27. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods* 2015;12:453-7.
28. Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. *Nat Med* 2018;24:1550-8.
29. Izzi V, Davis MN, Naba A. Pan-Cancer Analysis of the Genomic Alterations and Mutations of the Matrisome. *Cancers (Basel)* 2020;12:2046.
30. Frost FG, Cherukuri PF, Milanovich S, et al. Pan-cancer RNA-seq data stratifies tumours by some hallmarks of cancer. *J Cell Mol Med* 2020;24:418-30.
31. Sturm G, Finotello F, Petitprez F, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. *Bioinformatics* 2019;35:i436-45.
32. Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. *Immunity* 2018;48:812-30.e14.

- Erratum in: *Immunity* 2019;51:411-2.
33. Zhang Q, Huang R, Hu H, et al. Integrative Analysis of Hypoxia-Associated Signature in Pan-Cancer. *iScience* 2020;23:101460.
  34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646-74.
  35. Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. *Nat Rev Immunol* 2015;15:669-82.
  36. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. *Science* 2020;367:eaax0182.
  37. Yan M, Wang LC, Hymowitz SG, et al. Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. *Science* 2000;290:523-7.
  38. Jia N, Jia Y, Yang F, et al. Knockdown of EDA2R alleviates hyperoxia-induced lung epithelial cell injury by inhibiting NF- $\kappa$ B pathway. *Allergol Immunopathol (Madr)* 2022;50:84-90.
  39. Mikkola ML. The Edar subfamily in hair and exocrine gland development. *Adv Exp Med Biol* 2011;691:23-33.
  40. Punj V, Matta H, Chaudhary PM. X-linked ectodermal dysplasia receptor is downregulated in breast cancer via promoter methylation. *Clin Cancer Res* 2010;16:1140-8.
  41. Xu W, Li Y, Yuan WW, et al. Membrane-Bound CD40L Promotes Senescence and Initiates Senescence-Associated Secretory Phenotype via NF- $\kappa$ B Activation in Lung Adenocarcinoma. *Cell Physiol Biochem* 2018;48:1793-803.
  42. Ma C, Fu Q, Diggs LP, et al. Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. *Cancer Cell* 2022;40:986-98.e5.
  43. Mu CY, Qin PX, Qu QX, et al. Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis. *Chronic Dis Transl Med* 2015;1:36-41.
  44. Zarnegar B, He JQ, Oganessian G, et al. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. *Proc Natl Acad Sci U S A* 2004;101:8108-13.
  45. Mosca PJ, Hobeika AC, Clay TM, et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. *Blood* 2000;96:3499-504.
  46. Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. *Clin Immunol* 2021;226:108707.
  47. Xu Y, Wu Y, Zhang S, et al. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2. *Cell Rep* 2019;29:3435-47.e4. Erratum in: *Cell Rep* 2020;32:108000.
  48. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. *Ann N Y Acad Sci* 2011;1217:45-59.
  49. Li J, Jie HB, Lei Y, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. *Cancer Res* 2015;75:508-18.
  50. Pauken KE, Sammons MA, Odorizzi PM, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. *Science* 2016;354:1160-5.
  51. Mauri DN, Ebner R, Montgomery RI, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. *Immunity* 1998;8:21-30.
  52. Wu F, Watanabe N, Tzoni MM, et al. Thyroid MALT lymphoma: self-harm to gain potential T-cell help. *Leukemia* 2021;35:3497-508.
  53. Cheung TC, Osborne LM, Steinberg MW, et al. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment. *J Immunol* 2009;183:7286-96.
  54. Tamada K, Shimosaki K, Chapoval AI, et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. *J Immunol* 2000;164:4105-10.
  55. Šedý JR, Bjordahl RL, Bekiaris V, et al. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells. *J Immunol* 2013;191:828-36.
  56. Zhu YD, Lu MY. Increased expression of TNFRSF14 indicates good prognosis and inhibits bladder cancer proliferation by promoting apoptosis. *Mol Med Rep* 2018;18:3403-10.
  57. Boice M, Salloum D, Mourcin F, et al. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. *Cell* 2016;167:405-18.e13.
- (English Language Editor: J. Gray)

**Cite this article as:** Kang C, Yun F, Shi L, Jia Y, Liu X. Landscape of costimulatory molecule signature in breast cancer and its prognostic significance. *Ann Transl Med* 2023;11(2):59. doi: 10.21037/atm-22-6245